ACCESSWIRE
11 May 2022, 21:13 GMT+10
Class 1 Medical Device Registration Allows Nutriband To Explore New Product Manufacturing Opportunities Through Its Wholly Owned Subsidiary Active Intelligence LLC
ORLANDO, FL / ACCESSWIRE / May 11, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced its Active Intelligence LLC subsidiary has registered as a Class I medical device manufacturer with the U.S. Food and Drug Administration (FDA) to manufacture and distribute its proprietary AI Tape, to compete in the growing kinesiology tape market.
'The FDA medical device manufacturing registration for Active Intelligence represents a pivotal milestone that paves the way for commercial sales of our AI Tape product in the United States,' commented Gareth Sheridan, CEO of Nutriband. 'The registration will enable Active Intelligence to manufacture AI Tape under its own brand or through white label agreements with sales and marketing partners as well as explore new opportunities for contract manufacturing in the medical device space. We look forward to providing the market with updates on the progress in the coming months.'
AI Tape is a kinesiology tape that is placed on the skin to support for athletes recovering from sports injuries. Active Intelligence is also developing a line of medicated kinesiology tapes to assist athletes in the recovery process after physical injury. The global sports medicine market exceeded $5 billion in 2021 and is projected to grow at a 6.8% CAGR through 2028, reaching an estimated $8.9 billion, according to data from Statista.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes,'' 'anticipates,' 'expects' and words of similar import, constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's Form S-1, Form 10-K for the year ended January 31, 2020 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Investor Relations
RedChip Companies
Dave Gentry
NTRB@redchip.com
1-800-RED-CHIP (733-2447)
407-491-4498
SOURCE: Nutriband Inc.
Get a daily dose of Baltimore Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Baltimore Star.
More InformationDOLNI MORAVA, Czech Republic: The world's longest pedestrian suspension bridge has opened at a mountain resort in the Czech Republic. ...
SHAN STATE, Myanmar - According to an officer who participated in the assault, two local defense forces have destroyed a ...
TUNIS, Tunisia - The Tunisian navy said Saturday that it rescued 81 migrants, including 32 Bangladeshis, sailing from Libya to ...
ST. PETERSBURG, Florida: - A nearly $1 billion settlement has been agreed upon in a lawsuit brought by families of ...
The suspect is an 18-year-old white man heavily armed with tactical gear and a helmet, said Buffalo Police Commissioner Joseph ...
SAN JOSE, Costa Rica: President Rodrigo Chaves, who was sworn in as president on May 8, has declared a state ...
NEW YORK, New York - Weak economic news out of China undermined stocks on Wall Street on Monday. The major ...
ATLANTA, Georgia: Mercedes-Benz USA has requested drivers to stop driving some of their autos immediately due to braking problems.The announcement ...
KARACHI, Pakistan - The U.S. dollar climbed past Rs194 in the interbank market in Pakistan on Monday as analysts expressed ...
ROME, Italy: Italy has announced plans to sell state-owned ITA Airways, the successor to Alitalia, by the end of June, ...
SYDNEY, NSW, Australia - Stocks struggled for direction in Asia on Monday. Early gains evaporated later in the data, although ...
BEIJING, China: China's Green Valley Pharmaceutical company has prematurely ended an FDA approved study on its GV-971 to treat mild ...